Search

Your search keyword '"Kimchi, Eric T."' showing total 345 results
Start Over Author "Kimchi, Eric T."
345 results on '"Kimchi, Eric T."'

15. Abstract 205: Patient-derived organoids from surgically treated, localized non-small cell lung cancer as high-throughput drug testing platforms for conventional and repurposed drugs

Author

Manjunath, Yariswamy, primary, Nagaraj, Suvilesh Kanve, additional, Nussbaum, Yulia I., additional, Gadelkarim, Mohamed, additional, Staveley-O’Carroll, Kevin F., additional, Kimchi, Eric T., additional, Li, Guangfu, additional, Warren, Wesley, additional, Shyu, Chi-Ren, additional, Ciorba, Matthew, additional, Mitchem, Jonathan B., additional, and Kaifi, Jussuf T., additional

Published
2023
Full Text
View/download PDF

22. Epigenetic Regulation of Cancer Immune Cells

Author

Avella Patino, Diego M., primary, Radhakrishnan, Vijay, additional, Suvilesh, Kanve N., additional, Manjunath, Yariswamy, additional, Li, Guangfu, additional, Kimchi, Eric T., additional, Staveley-O’Carroll, Kevin F., additional, Warren, Wesley C., additional, Kaifi, Jussuf T., additional, and Mitchem, Jonathan B., additional

Published
2022
Full Text
View/download PDF

23. Abstract 267: Xenograft models of non-metastatic non-small cell lung cancer reveals micrometastasis-associated single cell composition

Author

Suvilesh, Kanve Nagaraj, primary, Nussbaum, Yulia I., additional, Radhakrishnan, Vijay, additional, Manjunath, Yariswamy, additional, Avella, Diego M., additional, Staveley-O’Carroll, Kevin F., additional, Kimchi, Eric T., additional, Chaudhuri, Aadel A., additional, Shyu, Chi-Ren, additional, Li, Guangfu, additional, Pantel, Klaus, additional, Warren, Wesley C., additional, Mitchem, Jonathan B., additional, and Kaifi, Jussuf T., additional

Published
2022
Full Text
View/download PDF

28. Team Integrated Enhanced Recovery (TIGER) Protocol after Adolescent Idiopathic Scoliosis Correction Lowers Direct Cost and Length of Stay While Increasing Daily Contribution Margins

Author

Lambrechts, Mark J., Boeyer, Melanie E., Tweedy, Nicole M., Gupta, Sumit K., Kimchi, Eric T., and Hoernschemeyer, Daniel G.

Subjects
Pain, Postoperative, Spinal Fusion, Treatment Outcome, Adolescent, Scoliosis, Science of Medicine, Humans, Length of Stay, Child, Hospitals, Pediatric, Retrospective Studies
Abstract

INTRODUCTION: Posterior spinal fusion (PSF) is the gold standard procedure for curve correction in Adolescent Idiopathic Scoliosis (AIS). Enhanced recovery protocols (ERPs) have been found to decrease pain and hospital length of stay (LOS) resulting in decreased total hospital charges. METHODS: We identified all adolescent idiopathic scoliosis patients treated with a posterior spinal fusion at our children’s hospital between 2015–2019. Length of stay, pain scores, and hospital direct costs were calculated to determine the pathway’s efficacy. RESULTS: Hospital LOS was reduced by 26% and post-op pain scores did not significantly change when using the Team Integrated Enhanced Recovery (TIGER) protocol (P

Published
2022

29. Additional file 4 of Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses

Author

Suvilesh, Kanve N., Nussbaum, Yulia I., Radhakrishnan, Vijay, Manjunath, Yariswamy, Avella, Diego M., Staveley-O���Carroll, Kevin F., Kimchi, Eric T., Chaudhuri, Aadel A., Shyu, Chi-Ren, Li, Guangfu, Pantel, Klaus, Warren, Wesley C., Mitchem, Jonathan B., and Kaifi, Jussuf T.

Abstract

Additional file 4. Supplementary methods.

Published
2022
Full Text
View/download PDF

40. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer

Author

Avella, Diego M., Kimchi, Eric T., Donahue, Renee N., Tagaram, Hephzibah Rani S., McLaughlin, Patricia J., Zagon, Ian S., and Staveley-OCarroll, Kevin F.

Subjects
Cell proliferation -- Physiological aspects, Cell proliferation -- Research, Hepatoma -- Genetic aspects, Hepatoma -- Care and treatment, Hepatoma -- Research, Biological sciences
Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, with a mortality rate approximating its incidence. Understanding the biology of these tumors, as well as treatment modalities, has been challenging. The opioid growth factor (OGF; [[Met.sup.5]]-enkephalin) and the OGF receptor (OGFr) form an endogenous growth-regulating pathway in homeostasis and neoplasia. In this investigation, we examined the relationship of the OGF-OGFr axis in HCC and define its presence, function, and mechanism. Using SK-HEP-1, Hep G2, and Hep 3B human HCC cell lines, we found that OGF and OGFr were present and functional. Exogenous OGF was observed to have a dose-dependent, reversible, and receptor-mediated inhibitory action on cell proliferation. Endogenous OGF was found to be constitutively produced and tonically active on cell replicative activities, with neutralization of this peptide accelerating cell proliferation. Silencing of OGFr using siRNA stimulated cell replication, even when exogenous OGF was added to the cultures, documenting its importance in mediating OGF activity. The mechanism of OGF-OGFr action on cell number was related to inhibition of DNA synthesis and not to apoptotic or necrotic pathways. Both OGF and OGFr were detected in surgical specimens of HCC, and no quantitative differences were recorded in peptide or receptor between pathological and normal specimens. These data are the first to report that the OGF-OGFr system is a native biological regulator of cell proliferation in HCC. The findings may provide important insight in designing treatment strategies for this deadly disease. hepatocellular carcinoma; cell proliferation; tissue culture; siRNA; therapy doi: 10.1152/ajprcgu.00646.2009

Published
2010

46. LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis

Author

Liu, Xinjian, primary, Yuan, Hao, additional, Zhou, Jing, additional, Wang, Qiongling, additional, Qi, Xiaoqiang, additional, Bernal, Catharine, additional, Avella, Diego, additional, Kaifi, Jussuf T., additional, Kimchi, Eric T., additional, Timothy, Parrett, additional, Cheng, Kun, additional, Miao, Yi, additional, Jiang, Kuirong, additional, and Li, Guangfu, additional

Published
2021
Full Text
View/download PDF

47. Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer

Author

Liu, Dai, Qi, Xiaoqiang, Manjunath, Yariswamy, Kimchi, Eric T., Ma, Lixin, Kaifi, Jussuf T., Staveley-O’Carroll, Kevin F., and Li, Guangfu

Subjects
Regulatory T cells (Tregs), Myeloid-derived suppressive cells (MDSCs), Hepatocellular cancer (HCC), Sunitinib, Chemoimmunotherapy, Sorafenib, urologic and male genital diseases, neoplasms, digestive system diseases, female genital diseases and pregnancy complications, Article
Abstract

Sorafenib and sunitinib are multiple tyrosine kinase inhibitors. Both of them have been approved by the US FDA in the treatment of patients with malignancies. In order to develop an effective and clinically useful chemoimmunotherapy modality against hepatocellular cancer (HCC), we investigate their tumoricidal and immune modulatory effect in the setting of HCC. In vitro experiments suggested that sunitinib and sorafenib both induced HCC cell apoptosis at an equivalent level, but stronger suppressive function to cell proliferation was detected in sorafenib. Correspondingly, treatment of tumor-bearing mice with sorafenib led to the suppression of tumor growth to a larger extent than sunitinib. Flow cytometry showed that treatment with sunitinib, not sorafenib, significantly reduced the frequency of regulatory T cells (Tregs) and myeloid-derived suppressive cells (MDSCs) in tumor-bearing mice; and allowed splenic lymphocytes to produce equivalent levels of IFN-γ and TNF-α in response to vaccination as that in wild type mice. This activation was not detected in control and sorafenib-treated tumor mice. In addition, treatment of tumor-bearing mice with sunitinib followed by adoptive transfer of tumor antigen-specific CD8+ T cells and immunization resulted in the additional suppression to tumor growth compared to sunitinib monotherapy. These results imply treatment with sunitinib, not sorafenib, is able to prevent tumor-induced immunotolerance and activate antitumorimmunity. Our data suggest that sunitinib may be a preferable chemotherapeutic agent to use in combination with immunotherapy for the treatment of HCC.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results